PT-141 (Bremelanotide) Research: Phase 3 RECONNECT Trials, Mechanism & Safety Data
PT-141 (bremelanotide) — the FDA-approved medicine Vyleesi — reviewed study by study: the RECONNECT phase 3 trials, the central MC4R mechanism, and the safety caveats that shape its clinical use.
Mechanism of action
Bremelanotide is a synthetic peptide analogue of natural alpha-melanocyte-stimulating hormone (α-MSH). It is structurally derived from Melanotan 2 but deliberately modified to remove the severe cardiovascular spikes and structural risks associated with its predecessor.
Unlike PDE5 inhibitors such as Viagra or Cialis, which act as peripheral vasodilators to increase blood flow, bremelanotide is a centrally acting psychotropic. It binds to melanocortin-4 receptors (MC4R) in the medial preoptic area of the hypothalamus.
MC4R activation triggers a rapid release of dopamine and norepinephrine, lighting up the core neural networks for desire, motivation and arousal upstream of the physical response.
A small residual affinity for MC1R explains the focal hyperpigmentation reported in a minority of patients, while MC4R activity is linked to the transient nausea and blood-pressure effects seen in the trials.
The studies
The published bremelanotide literature is built on a gold-standard human phase 3 foundation. The three study areas below cover HSDD, female sexual arousal disorder and the off-label male ED literature.
RECONNECT programme
RECONNECT (Studies 301 and 302) — hypoactive sexual desire disorder
To evaluate the efficacy and safety of on-demand subcutaneous bremelanotide 1.75 mg in premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD).
Over 1,200 premenopausal women across two identical multi-centre trials · 24 weeks · randomised, double-blind, placebo-controlled · self-administered sub-Q autoinjector
- Significant
- Improvement in desire score
- Significant
- Reduction in distress score
- Nausea
- Most common adverse event
vs placebo, both trials
vs placebo, both trials
~40%, mostly first dose
Benefits shown in the data
- Women taking subcutaneous bremelanotide recorded highly significant increases in sexual desire scores compared with placebo.
- The same group showed a massive, measurable reduction in the psychological distress and interpersonal anxiety caused by low libido.
- The integrated success of Studies 301 and 302 directly led to FDA approval of bremelanotide for acquired, generalised HSDD in premenopausal women.
- RECONNECT is the pivotal evidence base for bremelanotide and the reason it exists as an approved medicine (Vyleesi).
- Both co-primary endpoints — sexual desire and associated distress — were met in two independently powered trials.
- Nausea and transient blood-pressure elevation were the dose-limiting tolerability issues; most patients found nausea softened by the second or third dose.
Correcting female sexual arousal disorder (FSAD)
To test whether central MC4R activation automatically optimises physical, physiological genitourinary responses during sexual activity.
Randomised, double-blind, placebo-controlled human clinical trials tracking physical responsiveness, genital arousal sensations and satisfying sexual encounters
- Significantly higher
- Physical genital arousal
- Substantially greater
- Overall arousal satisfaction
- Central-to-physical bridge
- Mechanism
vs placebo
during intercourse
not peripheral vasodilation
Benefits shown in the data
- Patients reported significantly higher scores for physical genital arousal compared with placebo.
- Satisfaction with overall arousal levels during intercourse was substantially greater.
- The data showed that a centrally acting psychotropic can bridge the gap between mental desire and physiological performance.
- These trials extend the HSDD findings by showing downstream physiological benefit.
- The effect is not produced by mechanically pumping blood to the genitals; it is a consequence of central arousal pathways.
Off-label treatment for male erectile dysfunction
To evaluate bremelanotide in men with erectile dysfunction, particularly those who failed to respond to standard PDE5 inhibitor therapy.
Human clinical efficacy and comparative tracking of centrally acting treatments for organic and psychogenic male erectile dysfunction
- Clinically apparent
- Erectile response
- Increased
- Sexual desire
- MC4R central
- Mechanism
in PDE5 non-responders
independent of vascular status
not nitric-oxide vasodilation
Benefits shown in the data
- Bremelanotide induced firm, clinically apparent erections in men who were previously completely resistant to Viagra or Cialis.
- Baseline sexual desire also improved, giving a dual action that peripheral vasodilators do not provide.
- The response was driven by activating the brain's internal MC4R receptors rather than by peripheral vascular pathways.
- The official FDA indication is limited to premenopausal women with HSDD; male ED use is off-label and based on earlier development data and specialist urology practice.
- Because the mechanism is central, it can work even when peripheral vascular pathways are impaired.
Storage & handling
Bremelanotide research material is supplied as a lyophilised powder. Store sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until dissolved — do not shake.
Keep reconstituted solution at 2-8 °C and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
The clinical catch: nausea, blood pressure and pigmentation
The published literature outlines three safety caveats that require careful patient screening. They are well documented in the phase 3 trials and the FDA-approved product label.
Nausea
Nearly 40% of patients experienced sudden nausea immediately after the subcutaneous injection in the phase 3 trials, with 13% needing secondary anti-nausea medication. For most patients this nausea softened or disappeared by the second or third dose.
Transient hypertension
Bremelanotide causes a temporary increase in systolic and diastolic blood pressure with a corresponding drop in heart rate. The spikes peak around 2 to 4 hours post-injection and return to baseline within 12 hours. It is contraindicated for anyone with uncontrolled high blood pressure or known cardiovascular disease.
Focal hyperpigmentation
Because bremelanotide retains slight affinity for MC1R, roughly 1% of patients develop permanent or semi-permanent dark spots on the face, breasts or gums, particularly with frequent use.
Dosing frequency cap
The approved medical protocol is a single 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity, not more than once in 24 hours and not more than eight times per month.
Research use only
Vyleesi is the FDA-approved 1.75 mg autoinjector product for HSDD. Research vials sold online are unregulated and are not the approved medicine. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.